Anti -inflammatory substituted cyclobutenedione compounds

Details for Australian Patent Application No. 2008258588 (hide)

Owner Novartis AG

Inventors Watson, Simon James; Press, Neil John

Agent Davies Collison Cave

Pub. Number AU-B-2008258588

PCT Pub. Number WO2008/148790

Priority 07109704.2 06.06.07 EP

Filing date 4 June 2008

Wipo publication date 11 December 2008

Acceptance publication date 10 November 2011

International Classifications

C07D 207/09 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

A61K 31/341 (2006.01) - not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine

C07D 307/14 (2006.01) Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

Event Publications

24 December 2009 PCT application entered the National Phase

  PCT publication WO2008/148790 Priority application(s): WO2008/148790

13 May 2010 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the name Corrigenda Novartis AG, Application No. 2008258588, under INID (72) remove inventor Porter, David

10 November 2011 Application Accepted

  Published as AU-B-2008258588

8 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008258596-Controlled release pharmaceutical compositions for prolonged effect

2008258582-Cryptographic methods and devices for the pseudo-random generation of data encryption and cryptographic hashing of a message